Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDRH’s Shuren Calls For ‘Reset’ Of FDA Medtech Initiatives

Programs disrupted by COVID-19 would be restarted in 2021 to guide developers on clinical decision support software, produce safe OTC hearing aids

Executive Summary

US FDA device center director Jeff Shuren wants to hit the reset button for initiatives delayed by agency’s responses to the coronavirus pandemic.

You may also be interested in...

One-Two Punch Of HHS Rules On Guidance Docs, Regs Will ‘Tie Hands’ Of Biden Admin: Expert

Two new rules put forward by the US HHS could have a chilling effect on future guidance documents and regulations drafted by the FDA and the 27 other agencies and offices the HHS oversees, a policy expert says. This and other stories topped our list of most-read US regulation, policy, quality control and compliance articles in December.

FDA Guidances On Orthopedic, Imaging Devices Demonstrate Safety And Performance Pathway Use

The US agency released three new guidance documents on 10 December detailing how certain devices can be cleared through a safety and performance pathway.

FDA Official Confirms 2021 For Release Of Draft QSR, Asks For ‘Inclusive Comment Spectrum’

The US FDA’s Elizabeth Miller says the agency won’t release a draft of its revised Quality System Regulation until sometime next year. The FDA has been harmonizing its QSR with international quality systems standard ISO 13485:2016 since 2018.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts